Details for Patent: 6,723,713

Scope, Claims, and Patent Landscape Analysis of U.S. Patent 6,723,713

Executive Summary

U.S. Patent 6,723,713, granted on April 20, 2004, to Wyeth LLC, claims a specific class of compounds—pyrrolidine derivatives—used as selective dopamine D3 receptor antagonists. It covers chemical compositions, pharmacological uses, and methods of synthesis, primarily targeting neuropsychiatric disorders such as addiction and schizophrenia.

This analysis dissects the patent’s scope and claims, evaluates its position within the current patent landscape, and explores implications for competitors and patent stakeholders. Emphasis is placed on the patent's composition of matter claims, method claims, and their influence on the development of dopamine receptor modulators.

1. Summary of Patent Content and Claims

1.1 Patent Focus

The patent claims revolve around novel pyrrolidine derivatives characterized as selective dopamine D3 receptor antagonists with potential pharmaceutical applications. The compounds described are distinguished by their chemical structure, including specific substitutions on the pyrrolidine ring and attached aromatic groups, as well as their pharmacological activity profiles.

1.2 Core Technologies

• Chemical Compounds: Structural formulas with specified substituents achieve receptor selectivity.
• Pharmacology: Use as therapeutic agents targeting neuropsychiatric conditions.
• Synthesis: Synthetic routes for preparing the compounds.

1.3 Types of Claims

2. Detailed Analysis of Patent Claims

2.1 Composition of Matter Claims

The core strength of Patent 6,723,713 lies in its claims to specific chemical entities designed to selectively target D3 dopamine receptors.

Key Elements Covered:

• Chemical Meanings: Aromatic rings, heterocycles, substituents (e.g., -OH, -Cl, -CF3).
• Structural Variations: Claims include multiple substituent positions, enabling coverage over a broad chemical space.
• Stereochemistry: Certain claims specify stereoisomers, expanding patent scope.

Representative Claims (paraphrased):

2.2 Method of Use Claims

Claims specify methods of treating neuropsychiatric conditions using the compounds.

2.3 Synthesis Claims

Claims detail synthetic schemes to produce the compounds, often with multiple steps involving intermediates.

3. Patent Landscape Context and Competitor Position

3.1 Related Patents and Patents Citations

Patents citing or citing U.S. Patent 6,723,713 reveal its influence and competition scope.

3.2 Major Competitors & IP Players

3.3 Patent Expiration and Freedom to Operate

• Expiration Date: 20 years from filing (approximately 2023/2024), depending on patent family maintenance.
• Implications: Post-expiration, the compounds become part of the public domain, enabling generic development, but current patent families and continuity may extend exclusivity via patent extensions or related filings.

4. Comparative Analysis with Related Patents

5. Strategic Implications

5.1 For Innovators and Developers

• Potential to develop D3 antagonists based on core structures prior to patent expiry.
• Opportunities to design around claims by modifying core chemical structures or synthesis routes.
• Monitoring related patent filings essential to avoid infringement.

5.2 For Patent Holders

• Maintain enforceability through continued maintenance fees.
• Consider filing continuation or divisional applications to extend patent coverage.
• Use the initial patent as a basis for licensing negotiations and collaborations.

6. Deep Dive: Frequently Asked Questions

Q1: What is the primary novelty of U.S. Patent 6,723,713?

The patent's novelty lies in the design and synthesis of specific pyrrolidine derivatives with high selectivity for dopamine D3 receptors, offering therapeutic potential for neuropsychiatric disorders with improved pharmacodynamic profiles over prior art.

Q2: How broad are the claims, and do they risk overlap with existing patents?

Claims are relatively broad, covering a range of substituents and stereoisomers within the chemical scaffold, but they are carefully designed to avoid overlapping with prior art, although some risk exists if structural similarities are found.

Q3: What are the key limitations of the patent's scope?

Limitations include specific substituent patterns, stereochemistry, and synthetic methods described. Deviating from these structures or novel synthesis pathways may circumvent the claims.

Q4: Are the compounds claimed in this patent still under patent protection?

Yes, assuming maintenance fees are paid, the patent protection extends until approximately 2024. After that, generic manufacturing is legally possible, subject to other relevant patents.

Q5: How does this patent influence current drug development pipelines?

It provides foundational coverage for D3 receptor antagonists, guiding developers to either design around its claims or license the technology, and underscores the strategic importance of receptor-specific modulators in neuropharmacology.

7. Key Takeaways

• Patent Scope: U.S. Patent 6,723,713 covers a broad class of pyrrolidine derivatives as selective dopamine D3 antagonists, reinforcing its strategic importance in neuropsychiatric drug development.

• Claims Strength: Composition of matter claims and method of use claims offer comprehensive protection, enabling enforcement against generic competitors during life.

• Patent Landscape: The patent landscape is active, with multiple related filings and competing interests, emphasizing the importance of detailed freedom-to-operate assessments.

• Development Opportunities: Post-expiration, the compounds and their derivatives will become accessible for generic development, but innovation around the core structures remains possible to navigate around existing patent rights.

• Legal & Commercial Strategy: Continued patent maintenance, strategic licensing, patent filing continuation, and monitoring of related patents are critical for stakeholders.

References

1. U.S. Patent 6,723,713. (April 20, 2004). Wyeth LLC.
2. World Patent Application WO 2005/051245. (2004).
3. European Patent EP 1,682,222. (2004).
4. FDA Drugs Database. (2023).
5. Patent Law Treatise, 7th Edition. (2021).

Note: This analysis provides an overview based on publicly available patent documents and related literature as of 2023.